世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

結核ワクチン治療-世界市場シェアとランキング、全体売上高と需要予測 2025-2031

結核ワクチン治療-世界市場シェアとランキング、全体売上高と需要予測 2025-2031


Tuberculosis Vaccine Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

結核ワクチン治療の世界市場は、2024年には7830万米ドル規模と推定され、2031年には9540万米ドルに再調整され、予測期間2025-2031年のCAGRは2.9%と予測されている。 結核ワクチンは、主に結核に対して使用される... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年4月3日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

結核ワクチン治療の世界市場は、2024年には7830万米ドル規模と推定され、2031年には9540万米ドルに再調整され、予測期間2025-2031年のCAGRは2.9%と予測されている。
結核ワクチンは、主に結核に対して使用されるワクチンである。結核は重篤な感染症であり、肺や骨、関節、腎臓など身体の他の部分に影響を及ぼす。バシル・カルメット・ゲラン(BCG)ワクチンは80年前から存在し、現在のワクチンの中で最も広く使用されているワクチンの1つで、小児予防接種プログラムに組み込まれている国では、新生児と乳児の80%以上に接種されている。

その上、BCGワクチンはある種の膀胱癌の治療にも使用されている。膀胱癌は、膀胱壁の内壁に異常細胞や癌細胞が増殖したものである。BCGは、がんが膀胱内壁に再発するのを防ぎ、がんが浸潤するリスクを軽減する。
過去数年間、結核ワクチン治療の世界市場は順調に発展し、平均成長率は0.73%であった。
結核ワクチン治療薬の分類には免疫ワクチンと治療ワクチンがあり、2019年の免疫ワクチンの割合は約99.66%である。

結核ワクチン治療薬は自己調達、ユニセフ、その他を通じて広く販売されている。結核ワクチン治療薬は自己調達を通じて販売される割合が最も高く、2019年の割合は62.14%である。
アジア太平洋地域が最大の消費地であり、2019年の消費市場シェアは45%近くである。アジア太平洋に続き、中東・アフリカが2番目に大きな消費地で、消費市場シェアは35.66%である。
市場競争は激しい。メルク社、日本BCG研究所、インド血清研究所が業界のリーダーであり、市場の60%を占めている。
本レポートでは、結核ワクチン治療の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。

結核ワクチン治療の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データとともに、販売量(K Dose)と販売収益(百万ドル)で提供されます。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、結核ワクチン治療に関して十分な情報に基づいたビジネス上の意思決定を行えるよう支援します。

市場区分
企業別
メルク
日本BCG研究所
インド血清研究所
AJワクチン
バイオファーマ
グリーンシグナル・バイオファーマ
中国ナショナルバイオテック
バイオメッド・ルブリン
タージ・ファーマシューティカルズ
アタウルフォ・デ・パイヴァ
IVAC
クイーン・サオババ・メム研究所
マイクロジェン
タイプ別セグメント
免疫ワクチン
治療ワクチン
用途別セグメント
自己調達
ユニセフ
その他
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章: レポートの対象範囲、世界の総市場規模(金額、数量、価格)を紹介します。また、市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:結核ワクチン治療メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのを助ける。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのに役立ちます。
第5章:地域レベルでの結核ワクチン治療の売上高、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章:結核ワクチン治療の国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Tuberculosis Vaccine Treatment Product Introduction
1.2 Global Tuberculosis Vaccine Treatment Market Size Forecast
1.2.1 Global Tuberculosis Vaccine Treatment Sales Value (2020-2031)
1.2.2 Global Tuberculosis Vaccine Treatment Sales Volume (2020-2031)
1.2.3 Global Tuberculosis Vaccine Treatment Sales Price (2020-2031)
1.3 Tuberculosis Vaccine Treatment Market Trends & Drivers
1.3.1 Tuberculosis Vaccine Treatment Industry Trends
1.3.2 Tuberculosis Vaccine Treatment Market Drivers & Opportunity
1.3.3 Tuberculosis Vaccine Treatment Market Challenges
1.3.4 Tuberculosis Vaccine Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tuberculosis Vaccine Treatment Players Revenue Ranking (2024)
2.2 Global Tuberculosis Vaccine Treatment Revenue by Company (2020-2025)
2.3 Global Tuberculosis Vaccine Treatment Players Sales Volume Ranking (2024)
2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Company Players (2020-2025)
2.5 Global Tuberculosis Vaccine Treatment Average Price by Company (2020-2025)
2.6 Key Manufacturers Tuberculosis Vaccine Treatment Manufacturing Base and Headquarters
2.7 Key Manufacturers Tuberculosis Vaccine Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Tuberculosis Vaccine Treatment
2.9 Tuberculosis Vaccine Treatment Market Competitive Analysis
2.9.1 Tuberculosis Vaccine Treatment Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Tuberculosis Vaccine Treatment Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis Vaccine Treatment as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Vaccine
3.1.2 Therapy Vaccine
3.2 Global Tuberculosis Vaccine Treatment Sales Value by Type
3.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Type (2020-2031)
3.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Type (%) (2020-2031)
3.3 Global Tuberculosis Vaccine Treatment Sales Volume by Type
3.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (2020-2031)
3.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (%) (2020-2031)
3.4 Global Tuberculosis Vaccine Treatment Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Self-Procurement
4.1.2 UNICEF
4.1.3 Other
4.2 Global Tuberculosis Vaccine Treatment Sales Value by Application
4.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Application (2020-2031)
4.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Application (%) (2020-2031)
4.3 Global Tuberculosis Vaccine Treatment Sales Volume by Application
4.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (2020-2031)
4.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (%) (2020-2031)
4.4 Global Tuberculosis Vaccine Treatment Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Tuberculosis Vaccine Treatment Sales Value by Region
5.1.1 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025)
5.1.3 Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031)
5.1.4 Global Tuberculosis Vaccine Treatment Sales Value by Region (%), (2020-2031)
5.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region
5.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025)
5.2.3 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031)
5.2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Region (%), (2020-2031)
5.3 Global Tuberculosis Vaccine Treatment Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.4.2 North America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.5.2 Europe Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.7.2 South America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.8.2 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value
6.2.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.2.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.3.2 United States Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.4.2 Europe Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.5.2 China Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.5.3 China Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.6.2 Japan Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.7.2 South Korea Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.8.2 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.9.2 India Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.9.3 India Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Merck Tuberculosis Vaccine Treatment Product Offerings
7.1.5 Merck Recent Development
7.2 Japan BCG Lab
7.2.1 Japan BCG Lab Company Information
7.2.2 Japan BCG Lab Introduction and Business Overview
7.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Offerings
7.2.5 Japan BCG Lab Recent Development
7.3 Serum Institute of India
7.3.1 Serum Institute of India Company Information
7.3.2 Serum Institute of India Introduction and Business Overview
7.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Offerings
7.3.5 Serum Institute of India Recent Development
7.4 AJ Vaccines
7.4.1 AJ Vaccines Company Information
7.4.2 AJ Vaccines Introduction and Business Overview
7.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Offerings
7.4.5 AJ Vaccines Recent Development
7.5 BioFarma
7.5.1 BioFarma Company Information
7.5.2 BioFarma Introduction and Business Overview
7.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 BioFarma Tuberculosis Vaccine Treatment Product Offerings
7.5.5 BioFarma Recent Development
7.6 GreenSignal Bio Pharma
7.6.1 GreenSignal Bio Pharma Company Information
7.6.2 GreenSignal Bio Pharma Introduction and Business Overview
7.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Offerings
7.6.5 GreenSignal Bio Pharma Recent Development
7.7 China National Biotec
7.7.1 China National Biotec Company Information
7.7.2 China National Biotec Introduction and Business Overview
7.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Offerings
7.7.5 China National Biotec Recent Development
7.8 Biomed Lublin
7.8.1 Biomed Lublin Company Information
7.8.2 Biomed Lublin Introduction and Business Overview
7.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Offerings
7.8.5 Biomed Lublin Recent Development
7.9 Taj Pharmaceuticals
7.9.1 Taj Pharmaceuticals Company Information
7.9.2 Taj Pharmaceuticals Introduction and Business Overview
7.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Offerings
7.9.5 Taj Pharmaceuticals Recent Development
7.10 Ataulpho de Paiva
7.10.1 Ataulpho de Paiva Company Information
7.10.2 Ataulpho de Paiva Introduction and Business Overview
7.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Offerings
7.10.5 Ataulpho de Paiva Recent Development
7.11 IVAC
7.11.1 IVAC Company Information
7.11.2 IVAC Introduction and Business Overview
7.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 IVAC Tuberculosis Vaccine Treatment Product Offerings
7.11.5 IVAC Recent Development
7.12 Queen Saovabha Mem. Inst
7.12.1 Queen Saovabha Mem. Inst Company Information
7.12.2 Queen Saovabha Mem. Inst Introduction and Business Overview
7.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Offerings
7.12.5 Queen Saovabha Mem. Inst Recent Development
7.13 Microgen
7.13.1 Microgen Company Information
7.13.2 Microgen Introduction and Business Overview
7.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Microgen Tuberculosis Vaccine Treatment Product Offerings
7.13.5 Microgen Recent Development
8 Industry Chain Analysis
8.1 Tuberculosis Vaccine Treatment Industrial Chain
8.2 Tuberculosis Vaccine Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tuberculosis Vaccine Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Tuberculosis Vaccine Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for Tuberculosis Vaccine Treatment was estimated to be worth US$ 78.3 million in 2024 and is forecast to a readjusted size of US$ 95.4 million by 2031 with a CAGR of 2.9% during the forecast period 2025-2031.
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.

Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.
This report aims to provide a comprehensive presentation of the global market for Tuberculosis Vaccine Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tuberculosis Vaccine Treatment by region & country, by Type, and by Application.

The Tuberculosis Vaccine Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis Vaccine Treatment.

Market Segmentation
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Segment by Application
Self-Procurement
UNICEF
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Tuberculosis Vaccine Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Tuberculosis Vaccine Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Tuberculosis Vaccine Treatment Product Introduction
1.2 Global Tuberculosis Vaccine Treatment Market Size Forecast
1.2.1 Global Tuberculosis Vaccine Treatment Sales Value (2020-2031)
1.2.2 Global Tuberculosis Vaccine Treatment Sales Volume (2020-2031)
1.2.3 Global Tuberculosis Vaccine Treatment Sales Price (2020-2031)
1.3 Tuberculosis Vaccine Treatment Market Trends & Drivers
1.3.1 Tuberculosis Vaccine Treatment Industry Trends
1.3.2 Tuberculosis Vaccine Treatment Market Drivers & Opportunity
1.3.3 Tuberculosis Vaccine Treatment Market Challenges
1.3.4 Tuberculosis Vaccine Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tuberculosis Vaccine Treatment Players Revenue Ranking (2024)
2.2 Global Tuberculosis Vaccine Treatment Revenue by Company (2020-2025)
2.3 Global Tuberculosis Vaccine Treatment Players Sales Volume Ranking (2024)
2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Company Players (2020-2025)
2.5 Global Tuberculosis Vaccine Treatment Average Price by Company (2020-2025)
2.6 Key Manufacturers Tuberculosis Vaccine Treatment Manufacturing Base and Headquarters
2.7 Key Manufacturers Tuberculosis Vaccine Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Tuberculosis Vaccine Treatment
2.9 Tuberculosis Vaccine Treatment Market Competitive Analysis
2.9.1 Tuberculosis Vaccine Treatment Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Tuberculosis Vaccine Treatment Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis Vaccine Treatment as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Vaccine
3.1.2 Therapy Vaccine
3.2 Global Tuberculosis Vaccine Treatment Sales Value by Type
3.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Type (2020-2031)
3.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Type (%) (2020-2031)
3.3 Global Tuberculosis Vaccine Treatment Sales Volume by Type
3.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (2020-2031)
3.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (%) (2020-2031)
3.4 Global Tuberculosis Vaccine Treatment Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Self-Procurement
4.1.2 UNICEF
4.1.3 Other
4.2 Global Tuberculosis Vaccine Treatment Sales Value by Application
4.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Application (2020-2031)
4.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Application (%) (2020-2031)
4.3 Global Tuberculosis Vaccine Treatment Sales Volume by Application
4.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (2020-2031)
4.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (%) (2020-2031)
4.4 Global Tuberculosis Vaccine Treatment Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Tuberculosis Vaccine Treatment Sales Value by Region
5.1.1 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025)
5.1.3 Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031)
5.1.4 Global Tuberculosis Vaccine Treatment Sales Value by Region (%), (2020-2031)
5.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region
5.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025)
5.2.3 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031)
5.2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Region (%), (2020-2031)
5.3 Global Tuberculosis Vaccine Treatment Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.4.2 North America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.5.2 Europe Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.7.2 South America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value, 2020-2031
5.8.2 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value
6.2.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.2.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.3.2 United States Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.4.2 Europe Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.5.2 China Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.5.3 China Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.6.2 Japan Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.7.2 South Korea Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.8.2 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Tuberculosis Vaccine Treatment Sales Value, 2020-2031
6.9.2 India Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
6.9.3 India Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Merck Tuberculosis Vaccine Treatment Product Offerings
7.1.5 Merck Recent Development
7.2 Japan BCG Lab
7.2.1 Japan BCG Lab Company Information
7.2.2 Japan BCG Lab Introduction and Business Overview
7.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Offerings
7.2.5 Japan BCG Lab Recent Development
7.3 Serum Institute of India
7.3.1 Serum Institute of India Company Information
7.3.2 Serum Institute of India Introduction and Business Overview
7.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Offerings
7.3.5 Serum Institute of India Recent Development
7.4 AJ Vaccines
7.4.1 AJ Vaccines Company Information
7.4.2 AJ Vaccines Introduction and Business Overview
7.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Offerings
7.4.5 AJ Vaccines Recent Development
7.5 BioFarma
7.5.1 BioFarma Company Information
7.5.2 BioFarma Introduction and Business Overview
7.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 BioFarma Tuberculosis Vaccine Treatment Product Offerings
7.5.5 BioFarma Recent Development
7.6 GreenSignal Bio Pharma
7.6.1 GreenSignal Bio Pharma Company Information
7.6.2 GreenSignal Bio Pharma Introduction and Business Overview
7.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Offerings
7.6.5 GreenSignal Bio Pharma Recent Development
7.7 China National Biotec
7.7.1 China National Biotec Company Information
7.7.2 China National Biotec Introduction and Business Overview
7.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Offerings
7.7.5 China National Biotec Recent Development
7.8 Biomed Lublin
7.8.1 Biomed Lublin Company Information
7.8.2 Biomed Lublin Introduction and Business Overview
7.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Offerings
7.8.5 Biomed Lublin Recent Development
7.9 Taj Pharmaceuticals
7.9.1 Taj Pharmaceuticals Company Information
7.9.2 Taj Pharmaceuticals Introduction and Business Overview
7.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Offerings
7.9.5 Taj Pharmaceuticals Recent Development
7.10 Ataulpho de Paiva
7.10.1 Ataulpho de Paiva Company Information
7.10.2 Ataulpho de Paiva Introduction and Business Overview
7.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Offerings
7.10.5 Ataulpho de Paiva Recent Development
7.11 IVAC
7.11.1 IVAC Company Information
7.11.2 IVAC Introduction and Business Overview
7.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 IVAC Tuberculosis Vaccine Treatment Product Offerings
7.11.5 IVAC Recent Development
7.12 Queen Saovabha Mem. Inst
7.12.1 Queen Saovabha Mem. Inst Company Information
7.12.2 Queen Saovabha Mem. Inst Introduction and Business Overview
7.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Offerings
7.12.5 Queen Saovabha Mem. Inst Recent Development
7.13 Microgen
7.13.1 Microgen Company Information
7.13.2 Microgen Introduction and Business Overview
7.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Microgen Tuberculosis Vaccine Treatment Product Offerings
7.13.5 Microgen Recent Development
8 Industry Chain Analysis
8.1 Tuberculosis Vaccine Treatment Industrial Chain
8.2 Tuberculosis Vaccine Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tuberculosis Vaccine Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Tuberculosis Vaccine Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(tuberculosis)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/07 10:26

146.78 円

161.35 円

192.22 円

ページTOPに戻る